Parabolic Drugs Limited (PDL), a research based API (active pharmaceutical ingredients) manufacturer today announced its certification of European Union for its Cephalasporin manufacturing facility in Derabassi, Punjab.
The company has received approval for three of its molecules – namely, Cefuroxime Axetil, Cefpodoxime Proxetil and Cefixime Trihydrate. This will enable the company to sell its products into Europe, Canada and Australian markets, thus giving a boost to Company’s vision of building its business in regulated markets.
Commenting on the occasion, Vineet Gupta, Executive Director, Parabolic Drugs Ltd said “Parabolic already has a USFDA approval for selling one of its products in the US markets from its Panchkula facility. With this EU-GMP certification of its Derabassi facility, PDL has expanded its sales reach in the highly regulated markets and has positioned itself as a strong API company”.
The company has a stronghold in antibiotic space and marking its presence in the Custom Synthesis and Contract manufacturing (CRAMS) segment.
Content Guide
Parabolic Drugs Limited (PDL), a research based API (active pharmaceutical ingredients) manufacturer today announced its certification of European Union for its Cephalasporin manufacturing facility in Derabassi, Punjab.
